证券研究报告 | 2025年08月26日 纺织服饰·服装家纺 稳健医疗（300888.SZ） 优于大市 上半年收入同比增长 31%，医疗与消费协同发展 上半年收入同比增长 31%，营业利润率提升。受消费和医疗业务、以及内生 外延共同驱动下，2025 上半年公司营业收入同比+31.3%至 53.0 亿元，归母 净利润同比上升 28.1%至 4.9 亿元。盈利能力方面，毛利率整体基本维持稳 定；医疗业务受并表 GRI 影响，毛利率同比下降 0.7 个百分点至 37.4%；消 费品业务则受益于棉花价格下行及产品结构优化，毛利率同比提升 1.7 个百 分点至 58.6%。由于并购的 GRI 公司销售费用率较低，公司销售费用率同比 -2.5 百分点；管理/财务费用率分别同比+0.6/0.7 百分点。主要受益于费用 改善，整体经营利用率同比+0.7 百分点，医疗/消费品业务经营利润率分别 +1.0/1.2 百分点。最终归母净利率小幅下滑 0.2 百分点至 9.3%，主要受所 得税提升影响，所得税率提升主要因全棉时代占比提升及子公司迁址。上半 年每 10 股派发现金股利 4.5 元，共派发 2.62 亿元。 第二季度医疗业 ...

证券研究报告·公司点评报告·个护用品 稳健医疗（300888） 2025 年中报点评：双主业并驾齐驱，稳健向好 2025 年 08 月 25 日 增持（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 8,185 | 8,978 | 11,219 | 12,866 | 14,764 | | 同比（%） | (27.89) | 9.69 | 24.96 | 14.68 | 14.75 | | 归母净利润（百万元） | 580.40 | 695.38 | 1,044.52 | 1,237.42 | 1,494.17 | | 同比（%） | (64.84) | 19.81 | 50.21 | 18.47 | 20.75 | | EPS-最新摊薄（元/股） | 1.00 | 1.19 | 1.79 | 2.12 | 2.57 | | P/E（现价&最新摊薄） | 42.23 | 35.25 | 23.47 | 19.81 | 1 ...

[Table_Info1] [Table_Title] 证券研究报告 / 公司点评报告 消费品业务快速增长，品牌势能持续向上 --- 稳健医疗 2025 中报点评 事件： [Table_Summary] 公司发布 2025 年中报，2025H1 营业收入同比增长 31.3%至 53 亿元， 归母净利润同比增长 28.1%至 4.9 亿元。单 Q2 营业收入同比增长 26.7%至 26.9 亿元，归母净利润同比增长 20.7%至 2.4 亿元。 点评： 费用管控良好，盈利能力相对稳定。2025H1 公司毛利率同比下降 0.4pct 至 48.3%，医疗/消费品业务毛利率分别同比-0.7pct/+1.7pct 至 37.4%/58.6%。消费品业务毛利率提升主要得益于棉花价格下行及产品 结构改善。费用端，销售/管理费用率分别同比-2.5pct/+0.6pct。综合 2025H1 净利率同比下降 0.3pct 至 9.8%。 营运状况保持稳定。2025H1 公司存货同比增长 33.9%至 19.5 亿元，存 货周转天数同比下降 6 天至 142 天。应收/应付账款周转天数同比下降 1/16 天至 37/69 天。半 ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [3][6]. Core Insights - The company reported a strong performance in H1 2025, achieving revenue of 5.3 billion yuan, a year-on-year increase of 31.3%, and a net profit attributable to shareholders of 490 million yuan, up 28.1% year-on-year [5][6]. - The medical segment showed robust growth, with revenue of 2.52 billion yuan in H1, a year-on-year increase of 46.4%. Excluding the newly acquired GRI, the medical segment's revenue was 1.95 billion yuan, up 13.2% year-on-year [5][6]. - The consumer goods segment also performed well, with revenue of 2.75 billion yuan in H1, a year-on-year increase of 20.3%. The core product categories, such as sanitary napkins, saw significant growth, with revenue increasing by 67.6% [5][6]. Financial Performance Summary - H1 2025 revenue breakdown: - Medical segment: 2.52 billion yuan, up 46.4% year-on-year - Consumer goods segment: 2.75 billion yuan, up 20.3% year-on-year - H1 2025 net profit: 490 million yuan, up 28.1% year-on-year - H1 2025 gross margin: 48.3%, down 0.4 percentage points year-on-year [5][6]. Earnings Forecast and Investment Recommendations - The company plans to distribute a mid-term dividend of 260 million yuan, with a payout ratio of 53% [5][6]. - Forecasted net profits for 2025-2027 are 1 billion yuan, 1.21 billion yuan, and 1.45 billion yuan, with growth rates of 43.8%, 21.0%, and 19.7% respectively [5][6].

Core Insights - The company reported a significant increase in revenue and profit for the first half of 2025, with total revenue reaching 5.3 billion yuan, a year-on-year growth of 31.3%, and net profit attributable to shareholders at 490 million yuan, up 28.1% [1] - The medical and consumer segments both contributed to this growth, with revenues of 2.52 billion yuan and 2.75 billion yuan respectively, marking increases of 46.4% and 20.3% [1] Group 1: Consumer Segment Performance - The consumer brand, 全棉时代, achieved revenue of 2.75 billion yuan in the first half of 2025, reflecting a growth of 20.3% [2] - Key products such as the core dry and wet cotton soft towels saw sales increase to 810 million yuan, a growth of 19.5%, while sanitary napkins experienced a remarkable revenue increase of 67.6%, reaching 530 million yuan [2] - The brand's membership base grew to nearly 67 million, a 7.7% increase from the previous year, indicating strong customer loyalty and engagement [3] Group 2: Medical Segment Performance - The medical segment reported revenue of 2.52 billion yuan, a substantial increase of 46.4%, with organic growth excluding acquisitions contributing to a 13.2% rise [4] - Key innovations in the medical field included a 193.5% increase in revenue from surgical consumables, reaching 740 million yuan, and a 25.7% increase in high-end dressings, totaling 480 million yuan [4] - The company holds 1,109 R&D patents and 701 medical product registration certificates, establishing a strong foundation for future growth in both domestic and international markets [4] Group 3: Brand and Financial Strategy - The company announced a cash dividend distribution plan of 260 million yuan, representing 53.26% of net profit, reflecting a commitment to shareholder returns [5] - The brand aims to enhance its image and market position through various promotional activities and product innovations, reinforcing its commitment to quality and consumer health [5] - The company is focused on a long-term vision of sustainable growth, emphasizing the importance of brand elevation and maintaining industry leadership through continuous investment in R&D and quality control [5]

Summary of the Conference Call for稳健医疗 Company Overview - **Company Name**: 稳健医疗 (Steady Medical) - **Business Segments**: The company operates in two main segments: consumer products (52% of revenue) and medical supplies (48% of revenue) as of Q1 2025. The consumer products segment contributes approximately 60% to the overall operating profit margin [2][3]. Financial Performance - **Revenue Growth**: From 2013 to 2019, the company achieved a revenue growth rate of 24%, primarily driven by the consumer products segment. In Q1 2025, both medical supplies and consumer products segments returned to double-digit growth [2][5]. - **Profitability**: The company expects a 50% year-on-year increase in net profit attributable to the parent company in 2025, with the medical segment projected to grow by approximately 38% [4][19]. Market Dynamics - **Market Size**: The market for wet and dry cotton wipes is valued at over 10 billion yuan, with an expected growth rate of about 7%. The sanitary napkin market is around 100 billion yuan, with a projected retail price increase of about 3% in the coming years [2][6]. - **Market Share**: 全棉时代 (Cotton Era) holds over 15% market share in the facial towel category, while the overall market share of the company exceeds 20%, maintaining the leading position in this category [2][6]. Product Performance - **Core Products**: The core products, including dry and wet cotton wipes and sanitary napkins, have shown significant growth. The sanitary napkin brand, 奈斯公主 (Nice Princess), experienced over 70% year-on-year revenue growth in Q1 2025 [2][7][11]. - **Innovation**: The company introduced a hanging cotton wipe product, which significantly boosted market performance despite being a minor innovation [10]. Consumer Education and Brand Strategy - **Consumer Education**: The company emphasizes consumer education to enhance awareness of the quality and safety of cotton products, which has led to a recovery in double-digit growth for dry and wet cotton wipes [8][9]. - **Brand Positioning**: As a pioneer in the market, the company has established a strong brand identity, leveraging its unique product offerings and consumer education to differentiate itself from competitors [9][20]. Sales Channels - **Channel Distribution**: The consumer products segment has a channel distribution of approximately 60% online and 40% offline. The online sales have been particularly strong on platforms like Douyin [12][13]. - **Store Expansion**: The company operates 487 stores, with plans to open about 50 new stores annually while adjusting the store structure to improve performance [14]. Competitive Landscape - **Market Competition**: The low-value medical consumables market is highly competitive, with domestic brands primarily competing in the low-end market. The company aims to leverage its international presence and product quality to maintain a competitive edge [15][16]. Future Outlook - **Growth Projections**: The company anticipates strong growth in the consumer products segment, with cotton wipes expected to grow by 25% to 30% and sanitary napkins by over 50% in 2025 [18]. - **Net Profit Forecast**: The projected net profit for 2025 is 1.04 billion yuan, with continued growth expected in subsequent years [19]. - **Valuation**: The company's stock is currently valued at a PE ratio of approximately 30 times for 2025, which is considered reasonable given its diversified business model and strong product drivers [21]. Conclusion - **Investment Rating**: The company is viewed positively, with expectations of continued growth and a strong market position, leading to an optimistic outlook for future performance [22].

Group 1: Company Overview - Steady Medical Group, founded in 1991, has evolved into a health enterprise focusing on medical and consumer sectors, listed on the Shenzhen Stock Exchange in 2020 [13] - The company aims to "protect health, care for life, and protect the environment" with its main brands being "Winner Medical" and "Purcotton" [13] Group 2: Annual Performance Review - In 2024, the company achieved a total revenue of 89.8 billion CNY, a 9.7% increase from 2023's 81.9 billion CNY [18] - Excluding infection protection product revenue, the adjusted revenue was 86.2 billion CNY, reflecting an 18.6% year-on-year growth [18] - The revenue structure for 2024 was 43% from medical consumables and 56% from consumer products [18] Group 3: Profitability - The net profit attributable to shareholders reached 7.0 billion CNY, a 19.8% increase compared to 2023 [21] - The net profit margin improved to 7.7%, up 0.7 percentage points from the previous year [21] - The gross profit margin for 2024 was 47.3%, indicating a stable profitability trend [20] Group 4: Asset Quality and R&D Investment - Total assets at the end of 2024 were 184 billion CNY, a 7.5% increase from the previous year [26] - The asset-liability ratio stood at 35.4%, maintaining a low level [26] - The company emphasized R&D, with a steady increase in the number of patents and medical product registrations [26] Group 5: Shareholder Returns - The proposed cash dividend for 2024 is 3.8 billion CNY, representing 54% of the net profit [30] - Cumulative cash dividends since listing amount to 26.1 billion CNY, accounting for 93% of the net proceeds from the IPO [30] Group 6: Medical Consumables Business - The medical segment generated 39.1 billion CNY in revenue for 2024, showing resilience despite a high base from infection protection products [34] - Excluding infection protection, the medical consumables revenue was 35.5 billion CNY, a 20.4% increase year-on-year [34] - Core categories such as high-end dressings and surgical consumables saw revenue growth exceeding 30% [34] Group 7: Consumer Products Business - The consumer segment, led by Purcotton, achieved 49.9 billion CNY in revenue, a 17.1% increase from 2023 [43] - Online sales contributed 62% of the revenue, while offline stores accounted for 30% [46] - The company added 92 new offline stores in 2024, bringing the total to 487 [46] Group 8: Q1 2025 Performance Overview - In Q1 2025, total revenue reached 26.1 billion CNY, a 36.5% increase year-on-year [53] - The medical business revenue for Q1 2025 was 12.5 billion CNY, up 46.3% [54] - The consumer business generated 13.4 billion CNY, reflecting a 28.8% growth [54]

Core Viewpoint - The company reported a steady growth in revenue and net profit for 2024, with a significant increase in Q1 2025, indicating a positive trend in financial performance [3][4]. Financial Performance - In 2024, the company achieved a revenue of 8.98 billion yuan, a year-on-year increase of 9.7%, and a net profit attributable to shareholders of 700 million yuan, up 19.8% [3]. - For Q1 2025, the company reported a revenue of 2.61 billion yuan, representing a year-on-year growth of 36.5%, and a net profit of 250 million yuan, also up 36.3% [3]. Medical Consumables Segment - In 2024, the revenue from medical consumables accounted for 43.5% of total revenue, with a slight increase of 1.1% year-on-year. However, excluding the contribution from the acquired GRI, the revenue declined by 6.4% [4]. - The gross margin for medical consumables decreased by 3.9 percentage points to 36.5% in 2024, with a notable decline in the gross margin of infection protection products [4]. - In Q1 2025, the revenue from medical consumables surged by 46.3%, with a 10.5% growth when excluding GRI's impact [4]. Health and Lifestyle Products Segment - The health and lifestyle products segment accounted for 55.6% of total revenue in 2024, with a year-on-year growth of 17.1% and a slight decrease in gross margin by 1.0 percentage points [6]. - For Q1 2025, this segment's revenue grew by 28.8% year-on-year [6]. - Online and offline sales channels contributed to the revenue, with online sales growing by 18.9% and offline sales by 9.3% in 2024 [6][7]. Product Performance - In 2024, the revenue from infection protection products dropped significantly by 61.2%, while other product categories such as high-end wound dressings and surgical consumables showed strong growth [5]. - In Q1 2025, surgical consumables and high-end wound dressings experienced substantial growth rates of 196.8% and 21.1%, respectively [5].

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company reported strong performance in Q1, with significant contributions from both the medical and consumer goods sectors [1][13] - The revenue for 2024 reached 8.98 billion yuan, a year-on-year increase of 9.7%, while the net profit attributable to shareholders was 700 million yuan, up 19.8% [5][6] - The company has adjusted its profit forecasts for 2025 and 2026, increasing the net profit estimates by 17% and 18% respectively [13] Financial Performance - In Q1 2025, the company achieved a revenue of 2.61 billion yuan, representing a year-on-year growth of 36.5%, and a net profit of 250 million yuan, up 36.3% [6] - The medical consumables segment saw a revenue increase of 1.1% in 2024, while the consumer goods segment grew by 17.1% [7][9] - The gross profit margin for 2024 decreased by 1.7 percentage points to 47.3%, with a notable decline in the medical consumables segment [11][19] Revenue Breakdown - The medical consumables accounted for 43.5% of total revenue in 2024, with a significant contribution from the acquisition of GRI [7] - The consumer goods segment represented 55.6% of total revenue in 2024, with strong growth in online and offline sales channels [9][10] Future Projections - The company forecasts revenues of 11.17 billion yuan in 2025, with a growth rate of 24.4%, and a net profit of 1.02 billion yuan, reflecting a growth rate of 46.6% [14] - The projected EPS for 2025 is 1.75 yuan, with a P/E ratio of 30 [14][19]

Investment Rating - The report maintains a "Buy" rating for the company, indicating a strong performance relative to the market [1]. Core Insights - The company has shown accelerated growth in both of its main business segments, with a notable increase in dividend payout ratio to 54.4% from 50% in the previous year [6]. - The first quarter of 2025 saw a significant revenue increase of 36% year-on-year, reaching 2.61 billion yuan, with net profit also rising by 36.3% to 249 million yuan [7][6]. - The consumer goods segment continues to perform well, with a revenue growth of 28.8% in Q1 2025, driven by strong sales in key products [6]. - The medical business has shown resilience, with a 46.3% year-on-year growth in Q1 2025, despite previous high base effects [6]. Financial Data and Profit Forecast - Total revenue for 2024 is projected at 89.78 billion yuan, with a year-on-year growth of 9.7%, and a net profit of 6.95 billion yuan, reflecting a 19.8% increase [5]. - The company expects net profits to reach 10.3 billion yuan in 2025, corresponding to a PE ratio of 30 [6]. - The gross margin for 2024 is reported at 47.3%, with an anticipated recovery in margins for both consumer and medical segments in 2025 [6].